Skip to content
Screener

Exagen Inc. XGN Q4 2025 Annual earnings

Reported March 10, 2026 · Before market open

Revenue$16.6MBeat by $60.7K
EPS-$0.20In line
Revenue estimate$16.6M
EPS estimate-$0.20

Next report

Nov 3, 2026 (In 3 weeks)
Revenue estimate$18.3M
EPS estimate-$0.19

Financials

Q4 2025

Income statement

See full
Revenue$16.6M+21.8%
Gross profit$9.2M+8.6%
Operating income-$5.0M-47.1%
Net income-$4.7M-24.2%
EPS (diluted)-$0.200.0%

Balance sheet

See full
Cash & equivalents$32.4M+45.8%
Total debt$27.7M+18.4%
Total equity$17.4M+82.9%
Total assets$58.0M+29.8%

Cash flow

See full
Operating cash flow-$3.0M—
CapEx$44.0K-69.9%
Free cash flow-$3.1M—

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$137.79M+90.5%
Enterprise value$133.04M+81.2%
P/S2.1×+0.8×

Profitability

See full
Gross margin58.3%-1.2pp
Operating margin-21.1%-2.6pp
Net margin-30%+3.4pp

Returns & leverage

See full
Return on equity-147.8%+201pp
Debt / equity1.6×-0.9×
Current ratio3.5×+0.8×

Segments

By segment

See full
Reportable Segment$16.6M+21.8%

FAQ

When did Exagen Inc. report Q4 2025 earnings?
Exagen Inc. (XGN) reported Q4 2025 earnings on March 10, 2026 before market open.
What were Exagen Inc.'s Q4 2025 revenue and EPS?
Exagen Inc. reported revenue of $16.6M and eps of $-0.20 for Q4 2025.
Did Exagen Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $16.6M by $60.7K. EPS beat the consensus estimate of $-0.20 by $0.00.
How did Exagen Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 21.8% from $13.7M a year earlier and eps grew 0.0% from $-0.20.
Where can I find Exagen Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001274737-26-000007) and the 10-K periodic report (0001274737-26-000009) directly on SEC EDGAR. The filing index links above go to sec.gov.